Share This!©DisneyMany people dream of walking the red carpet and holding that beautiful golden statue, thanking their friends and family. Well, since I doubt you’ll have the opportunity to do that, here’s the next best thing for those of you who are fans of The Oscars.For a limited time, Guests who visit Disney’s Hollywood Studios’s One Man’s Dream will have the once-in-a-lifetime chance to see and take a photo with a gorgeous Oscar statuette.During this unique experience, Guests will have the opportunity to walk the red carpet and pose with the Oscar statue, against a signature Oscar backdrop. Oh and make sure to share your experience on social media using the hashtag, #Oscars.This wonderful opportunity will be available for Guests to take part in only until February 26.The Oscars will air this Sunday, February 26, on ABC at 7:00 p.m. ET/4:00 p.m. PT and will feature host Jimmy Kimmel.
Loading …Voting is open now here and on Twitter, and feel free to comment about why you made your choice. We’ll see you next week to crown yet another winner in the saga of Ask It! As I’m writing this up, I can hear the sounds of the fireworks from Wishes from outside my home office. Without looking up, I can tell from the sounds of the shells what “scene” is going on for the show. It will certainly be an adjustment when the new “Happily Ever After” nighttime spectacular debuts later this spring. It seems that everyone has a favorite nighttime show at Walt Disney World — so here’s this week’s question:What is your favorite current nighttime show at Walt Disney World Wishes (46%, 358 Votes) Illuminations (30%, 230 Votes) Fantasmic (21%, 163 Votes) Rivers of Light (3%, 23 Votes) Total Voters: 774 Share This!
On November 11, @shrmnextchat chatted with special guest Michael Jacobson (@HRTerminator) of Xpert HR about “Sexual Harassment: The Final Frontier of Workplace Gender Equality.” In case you missed it, here are all the informative tweets from the chat: [View the story “#Nextchat RECAP: Sexual Harassment – The Final Frontier of Workplace Gender Equality” on Storify]
Kathryn Shelton is Director of Chapter Advancement for America’s Future Foundation. AFF San Francisco officially launched with a Happy Hour on Thursday, April 23, 2015. 40 liberty-minded locals gathered at the Slate SF lounge to toast liberty and celebrate AFF’s expansion to the West Coast. Located in the heart of San Francisco’s Mission District – an historic and iconic cultural neighborhood – Slate SF provided an ideal setting to discuss and celebrate America’s history, exceptionalism and future.The evening began with a welcome from Paul Doherty, AFF-San Francisco’s Chapter Leader, followed by remarks from Sally Pipes, President and CEO of the Pacific Research Institute.Sally discussed PRI’s mission and recent work, and then spoke about Obamacare and its alternatives. She concluded that young people need to have an active voice for liberty in order to make real social change.
JEFFERSON CITY, Mo. (AP) – Missouri utility regulators have approved the acquisition of a large wind energy project by a Chicago firm.The decision Wednesday by the state Public Service Commission was a necessary step for Invenergy to buy the rights to construct the proposed Grain Belt Express power line.The project initiated by Houston-based Clean Line Energy Partners would carry Kansas wind energy on a 780-mile (1,255-kilometer) path across Missouri and Illinois before hooking into an electric grid in Indiana that serves eastern states.Missouri regulators earlier this year reversed their previous denials and gave the green light to the project. Missouri legislators then tried but failed to prohibit eminent domain for the project.But the project still needs regulatory approval in Illinois, where an appeals court last year overturned the state’s previous approval. Invenergy’s acquisition also needs approval in Kansas.
Gene therapy stops bleeding episodes in hemophilia trial By Jocelyn KaiserDec. 6, 2017 , 5:00 PM iStock.com/somersault18:24 Researchers have scored their first clear success in using gene therapy to treat hemophilia, an inherited blood disorder. Ten men received a single intravenous infusion of a harmless virus ferrying a gene for factor IX, a blood-clotting protein missing in people with hemophilia B. Up to 18 months later, the men’s livers are making, on average, 34% the normal level of factor IX. That’s enough that nine of the 10 patients have had no bleeding episodes, researchers report today in The New England Journal of Medicine. What’s more, eight of the 10 no longer need factor IX injections every few days. Previous gene therapy trials for hemophilia B didn’t go well, either because patients’ immune systems destroyed the modified cells or the cells didn’t make enough factor IX. In the new trial, sponsored by Spark Therapeutics and Pfizer, researchers gave the patients’ liver cells the gene for an unusually potent version of the factor IX protein. That allowed the team to lower the vector dose, minimizing immune responses. Two patients had elevated liver enzymes in reaction to the vector, but those levels came down after they received steroids. Only 20% of hemophilia patients have the B form, but efforts are also underway to use gene therapy to treat the most common type, hemophilia A.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)